Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2026-07-01 13:39:50 ET · period of report 2026-06-30 · accession 0001104659-26-079792 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 13:39 | 2026-06-30 | NVCT | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $20.00 | +12.5K | 3.69M | +0.3% | +$250.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-30 | P | A | 12,500 | $20.00 | 3,688,424 | D | — | — | (F1) Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026. (F2) Includes shares of restricted common stock. |